Recombinant herpes zoster vaccine composition and application thereof

A recombinant herpes zoster vaccine composition, comprising gE protein of varicella zoster virus (VZV) and a pharmaceutically acceptable combined adjuvant, wherein the pharmaceutically acceptable combined adjuvant is an aluminum adjuvant combined with a CpG adjuvant, a content of the gE protein is 50-100 μg, a content of the aluminum adjuvant is 225-600 μg, and a content of the CpG adjuvant is 300-900 μg.